Do the terms biosimilars, follow-on proteins, follow-on biologics, biogenerics all mean the same thing?
Biosimilars is the accepted regulatory term in the US and EU for biopharmaceutical products approved via a specific abbreviated regulatory pathway. In the US, this approval pathway was established in March 2010 with the Patient Protection and Affordable Care Act (PPAC). Follow-on protein products (FOPPs) and follow-on biologics are similar terms. Biologics, or biological medicines, is another term for biopharmaceuticals. Biogenerics is not a generally accepted regulatory term.
